Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tinhofer

Showing results (131-140 of 195) with videos related to

Pageof 20
Sort By:
F1000Research|April 5, 2021
PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot studyJulian Rogasch, Marcus Beck, Carmen Stromberger, et al.
Oncology Research and Treatment|December 22, 2025
Frontline pembrolizumab or methotrexate in elderly, frail, or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - results of the randomized phase 2 study ELDORANDO (AIO-KHT-0115)Konrad Klinghammer, Ullrich Graeven, Philipp Ivanyi, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
Cancers|January 21, 2022
Predictors for Adherence to Treatment Strategies in Elderly HNSCC PatientsRaphaela Graessle, Carmen Stromberger, Max Heiland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2010
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categoriesM Fiegl, M Erdel, I Tinhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 30, 2024
Feasibility analysis of using patient-derived tumour organoids for treatment decision guidance in locally advanced head and neck squamous cell carcinomaAnne-Sophie Fisch, Ana Pestana, Vanessa Sachse, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Oral Oncology|February 24, 2021
Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective studySebastian Zschaeck, Julian Weingärtner, Pirus Ghadjar, et al.
HNO|October 29, 2015
[HPV-associated head and neck cancer : mutational signature and genomic aberrations]S Wagner, N Würdemann, C Hübbers, et al.
Radiation Oncology (London, England)|August 1, 2021
Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)Minli Niu, Stephanie E Combs, Annett Linge, et al.
Pageof 20

Showing results (131-140 of 195) with videos related to

Sort By:
Pageof 20
F1000Research|April 5, 2021
PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot studyJulian Rogasch, Marcus Beck, Carmen Stromberger, et al.
Oncology Research and Treatment|December 22, 2025
Frontline pembrolizumab or methotrexate in elderly, frail, or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - results of the randomized phase 2 study ELDORANDO (AIO-KHT-0115)Konrad Klinghammer, Ullrich Graeven, Philipp Ivanyi, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
Cancers|January 21, 2022
Predictors for Adherence to Treatment Strategies in Elderly HNSCC PatientsRaphaela Graessle, Carmen Stromberger, Max Heiland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2010
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categoriesM Fiegl, M Erdel, I Tinhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 30, 2024
Feasibility analysis of using patient-derived tumour organoids for treatment decision guidance in locally advanced head and neck squamous cell carcinomaAnne-Sophie Fisch, Ana Pestana, Vanessa Sachse, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Oral Oncology|February 24, 2021
Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective studySebastian Zschaeck, Julian Weingärtner, Pirus Ghadjar, et al.
HNO|October 29, 2015
[HPV-associated head and neck cancer : mutational signature and genomic aberrations]S Wagner, N Würdemann, C Hübbers, et al.
Radiation Oncology (London, England)|August 1, 2021
Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)Minli Niu, Stephanie E Combs, Annett Linge, et al.
Pageof 20